ReviewGenes & diseases2027
Disulfidptosis-based cancer therapy: Opportunity and challenge.
Review in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer represents a significant global health threat, with traditional treatment modalities often facing substantial limitations. Consequently, novel therapeutic strategies have garnered considerable interest. In recent years, regulated cell death has achieved remarkable success in cancer treatment, as it is crucial for eliminating abnormal cells. Strategies aimed at inducing regulated cell death, especially disulfidptosis, have become increasingly important in cancer therapy. As a newly identified form of cell death, disulfidptosis has attracted growing attention in cancer research. This process is intricately linked to cystine uptake, consumption, and alterations in the actin cytoskeleton. In addition, disulfidptosis has been effectively utilized in bioinformatics research and has emerged as a biomarker for various cancer types, with the potential to serve as a therapeutic target. This review provides a comprehensive analysis of the canonical disulfidptosis signaling pathway, recent research advancements, and its application potential in oncology. We also examine current bioinformatics-derived biomarkers and potential targets. Crucially, we explore potential research directions for disulfidptosis in cancer and identify existing research challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.